Triple agonist peptides targeting glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR) have demonstrated superior therapeutic efficacy compared to single or dual agonist approaches in treating type 2 diabetes and obesity (Samms et al., 2020). Here, GCGR is linked to obesity disorder.